drugset / Trial / NCT00924352
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase 1/2
Completed
56 enrolled
Accelerated Community Oncology Research Network
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) and for the Phase II portion of the study is to evaluate progression free survival (PFS). Secondary objectives are response rate, clinical benefit rate, and overall toxicity.
Timeline
- Start
- 2009-06
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 12 mg/m2 | — |
| Subject | Ixabepilone | Small molecule | 16 mg/m2 | — |
| Subject | Ixabepilone | Small molecule | 20 mg/m2 | — |
| Subject | dasatinib anhydrous | Small molecule | 70 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | — |